je.st
news
Court ruling clears way for Novartis' low-cost biotech drug
2015-07-21 22:41:33| Biotech - Topix.net
A federal appeals court has ruled that Novartis can begin selling its lower-cost copy of an Amgen Inc. drug in September, rejecting a bid to further delay the launch of the knock-off biotech medication. Novartis received federal approval in March to sell its cheaper copy of Amgen's Neupogen, which is used to boost blood cells in cancer patients.
Tags: court
drug
ruling
biotech
Category:Biotechnology and Pharmaceuticals